Company news

MeiraGTx Holdings plc news in 2026

MeiraGTx Holdings plc's news releases, calls and decks from 2026, newest first.

View company

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

October 27, 2026

MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors

September 23, 2026

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

August 13, 2026

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

July 7, 2026

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 14, 2026

Company announcement: amendment notice

April 20, 2026

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

April 15, 2026

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

April 15, 2026

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

April 14, 2026

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

March 25, 2026

ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy

February 2, 2026

Corporate Deck January

January 13, 2026

Decks in 2026